Each Uroxate Tablet contains 100 mg Flavoxate hydrochloride.
Uroxate is a white round and slightly biconvex film-coated tablet embossed
with "SPS" on one side and plain on the other.
Flavoxate hydrochloride is a non-specific, direct acting smooth muscle
relaxant. It counteracts smooth muscle spasm of the urinary tract and has
been reported to produce an increase in urinary bladder capacity in patients
with evidence of bladder spasticity.
There are very limited published reports on the pharmacokinetic data on
flavoxate. In a single study of 11 normal male subjects, the time to onset
of action is 55 minutes after oral administration. Peak plasma concentration
was observed at 112 minutes and 57% of the flavoxate hydrochloride was
excreted via the kidneys within 24 hours in this particular study. It has
also been reported that 10-30% of a 100 mg dose is excreted in urine within
6 hours after oral administration.
Uroxate Tablet is used as an antispasmodic to provide symptomatic relief of
dysuria, urgency, nocturia, suprapubic pain, frequency and incontinence that
may occur in patients with cystitis, prostatitis, urethritis,
urethrocystitis and urethrotrigonitis.
Uroxate Tablet is contraindicated in patients with pyloric or duodenal
obstruction, obstructive intestinal lesions or ileus, achalasia,
gastrointestinal haemorrhage. or obstructive uropathies of the lower urinary
Flavoxate hydrochloride has antimuscarinic effects, concomitant use of two
or three such drugs potentiate the side effects such as dry mouth, urine
retention and constipation. Concomitant use with other antimuscarinic drug
may also lead to confusion in the elderly.
The incidence of adverse effects of Uroxate Tablet compared with other
antispasmodic is low with the following having been reported:-
GI Tract - nausea, vomiting, dry mouth, diarrhoea;
CNS - vertigo, headache, drowsiness, mental confusion especially in the
elderly, fatigue, nervousness and hyperpyrexia;
Haematologic - reversible leukopenia and eosinophilia;
Cardiovascular - tachycardia and
Allergic - urticaria and other
Ophthalmic - increase ocular tension, blurred vision, disturbance in eye
Renal - dysuria.
Precautions and Warnings
Patients should be warned that if drowsiness and blurred vision occur, they
should not drive, operate machinery or participate in activities where
alertness is required. Uroxate Tablet should be given cautiously in patients
with suspected glaucoma.
Use in pregnancy - The safety of flavoxate hydrochloride in
pregnant women has not been established. As such Uroxate Tablet should be
given to pregnant women only under compelling reasons, and when in the
opinion of the doctors, the potential benefits justify the potential risks
to the mother and foetus.
Nursing mothers - Since it is not known whether flavoxate
hydrochloride is excreted in human milk, Uroxate Tablet should be
administered to nursing mothers with caution.
Paediatric Use - The safety and efficacy of flavoxate
hydrochloride in children below the age of 12 years have not been
established. As such Uroxate Tablet is not recommended for use in infants
and children in this age group.
Adults and children over 12 years old: one or two 100 mg tablets to be taken
three or four times daily. The dose may be reduced with improvement in
Overdosage and Treatment
Symptoms of overdosage developing soon after ingestion of the drug include:
tachycardia, palpitation, dry mouth, blurred vision, speech disturbance,
drowsiness, difficulty in swallowing, restlessness, diarrhoea or
constipation, dry hot skin and fever.
Treatment - Gastric lavage and other measures to limit
intestinal absorption should be initiated without delay. Administration of
parasympathetic drugs should also be considered.
Box of 10 x 10 tablets.
Bottle of 500 tablets.
Store in a cool dry place, below 30°C
Protect from light.
Keep all medicines out of the reach of children.
Refer to outer Box